Orthocell Ltd has released a press release.
Key Executives Appointed to Drive Remplir US Sales
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- Orthocell completes $17m Placement
- $17m Placement to Drive Further Growth as US Approval Nears
- Regulatory approval to commence Remplir sales in Singapore
- Second Consecutive Record Quarter as Revenue Exceeds $2m
- First sales of Striate in major new market of Canada
Later from Orthocell
- Distributor Signed, Remplir Sales in Singapore to Commence
- Outstanding Remplir Study Results Pave Way for FDA Clearance
- Major Milestone with First Sales of Remplir in Singapore
- US FDA Application Submitted for Remplir as US Launch Nears
- Third Consecutive Quarter of Record Revenue for Orthocell
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell